CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Benralizumab 25 mg +3 morebiological
Likely dose
Benralizumab 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00783289
NCT00783289Phase 2Completed
CompareCT.gov

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple-dose Subcutaneous Administration of MEDI-563, a Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, in Adults With Asthma

MedImmune LLC·interventional·Posted Oct 31, 2008·Updated Dec 27, 2019

In Brief

A Phase 2 clinical trial evaluating Placebo, Benralizumab 25 mg, and 2 other interventions for Asthma. Completed, enrolled 35 participants across 6 sites.

Detailed Summary

The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 31, 2008
Enrollment StartNov 14, 2008
Primary CompletionNov 17, 2009
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 17.7 years ago

Interventions

Placeboother

Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.

Benralizumab 25 mgbiological

Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.

Benralizumab 100 mgbiological

Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.

Benralizumab 200 mgbiological

Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.